Article

Cyclosporine A tested for dry eye

Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome.

Tampa, FL-Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome.

Sirion Therapeutics Inc. has initiated a phase III clinical trial testing cyclosporine (ST-603). Meanwhile Novagali Pharma announced it has received FDA approval to launch a phase III trial of its cyclosporine A ocular product (Nova22007).

Novagali's product is designed to treat patients with moderate-to-severe dry eye syndrome. It is a proprietary cationic emulsion developed to provide optimal penetration of cyclosporine A in tissues of the eye surface.

The company met with the FDA in July 2006 to review the quality, safety, and efficacy data generated in the European phase II clinical study in patients with Sjögren's syndrome associated with keratoconjunctivitis sicca.

Sirion Therapeutics also announced it is launching a phase III trial of another pipeline compound, difluprednate (ST-601), for the treatment of anterior uveitis.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.